TOCA Tocagen Inc.

0.81
-0.04  -5%
Previous Close 0.85
Open 0.83
Price To Book 0.53
Market Cap 19,356,794
Shares 23,897,277
Volume 465,488
Short Ratio
Av. Daily Volume 711,462

NewsSee all news

  1. Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer

    SAN DIEGO, Sept. 12, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating

  2. Tocagen to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall, chief executive officer, will present and webcast at the Baird

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 primary and secondary endpoints missed - September 12, 2019.
Toca 511 & Toca FC - Toca 5
Recurrent brain cancer
Phase 1b update due 4Q 2019.
Toca 511 (Toca 6)
Solid tumors
Phase 1 updated data at AACR April 3, 2019.
Toca 511 & Toca FC
Glioma
Phase 2/3 enrolment to commence late 2019.
Toca 511 & Toca FC - (NRG-BN006)
Glioblastoma (GBM)

Latest News

  1. Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer

    SAN DIEGO, Sept. 12, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating

  2. Tocagen to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall, chief executive officer, will present and webcast at the Baird